Atlas Trials

Combination of Chemopreventive Agents (All- Trans Retinoic Acid and Tamoxifen) as Potential Treatment for the Lung Complication of COVID-19

Clinical trial NCT04568096 · UNKNOWN

Trial details

NCT number
NCT04568096
Sponsor
Kafrelsheikh University
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
the Lung Complication of COVID-19
Start date
2020-11-01
Primary completion
2020-12-01
Enrollment
160

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.